ELVN | Enliven Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	17.82 - 19.22
52 Week Range	13.30 - 30.03
Beta	1.66
Implied Volatility	78.13%
IV Rank	35.89%
Day's Volume	152,301
Average Volume	262,585
Shares Outstanding	49,004,400
Market Cap	928,143,336
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-03-12

Valuation
Profitability
Growth
Health
P/E Ratio	-10.02
Forward P/E Ratio	N/A
EPS	-1.89
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	46
Country	USA
Website	ELVN

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

ELVN's peers: CRMD, ETON, CMPX, GANX, IMRX, INBX, ORIC, PCSA, PRAX, URGN, MLTX, LIPO, THRX, PMVP, CGEM, AVTE, GPCR, REPL, NVCT, LYRA, KRON, GOSS, ELYM, MACK, CELC

*Chart delayed

Analyzing fundamentals for ELVN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ELVN Fundamentals page.

Watching at ELVN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ELVN Technicals page.